
The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) has issued two final decisions in a patent infringement lawsuit brought by 10x Genomics against single-cell sequencing firm Parse Biosciences ruling that all claims associated with two patents were invalid.
The rulings were based on a review requested by Parse of all claims for the two patents, 10,697,013 and 10,240,197 (known as the '013 and '197 patents, respectively). On January 31, the PTAB ruled that all 26 claims of the 1197 patent were unpatentable; all 28 claims of the '013 patent were ruled unpatentable in the final decision issued on February 3. Claims associated with a third patent (10,155,981) had previously been ruled invalid.
In addition, 10x Genomics has patent infringement litigation against NanoString/Bruker, which is ongoing in both the U.S. and Europe.